Targeted Doublet Improves Survival in MET-Positive Progressive Lung Cancer

(MedPage Today) -- Patients with MET-altered advanced non-small cell lung cancer (NSCLC) lived significantly longer with a targeted combination after progression on standard-of-care osimertinib (Tagrisso), a large randomized trial showed. Median...

Read it at MedPage Today ↗

← Front page